share_log

In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics

In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics

對Viridian Therapeutics的11條分析師推薦進行深入研究
Benzinga ·  11/13 11:00

During the last three months, 11 analysts shared their evaluations of Viridian Therapeutics (NASDAQ:VRDN), revealing diverse outlooks from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings83000
Last 30D10000
1M Ago10000
2M Ago11000
3M Ago52000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.18, along with a high estimate of $61.00 and a low estimate of $27.00. This current average reflects an increase of 9.39% from the previous average price target of $36.73.

bigjpg

Interpreting Analyst Ratings: A Closer Look

The standing of Viridian Therapeutics among...

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論